Barclays reaffirmed their overweight rating on shares of Hinge Health (NYSE:HNGE - Free Report) in a research note published on Monday morning, MarketBeat Ratings reports. They currently have a $51.00 price objective on the stock, up from their previous price objective of $43.00.
A number of other analysts have also issued reports on the company. Royal Bank Of Canada initiated coverage on Hinge Health in a research note on Monday, June 16th. They set an "outperform" rating and a $45.00 price objective on the stock. Morgan Stanley began coverage on Hinge Health in a research report on Monday, June 16th. They set an "overweight" rating and a $46.00 price objective on the stock. Needham & Company LLC began coverage on Hinge Health in a report on Monday, June 16th. They set a "buy" rating and a $47.00 target price for the company. Evercore ISI began coverage on Hinge Health in a report on Monday, June 16th. They set an "outperform" rating and a $50.00 target price for the company. Finally, Truist Financial began coverage on Hinge Health in a report on Monday, June 16th. They set a "buy" rating and a $48.00 target price for the company. One analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $49.36.
Get Our Latest Report on HNGE
Hinge Health Stock Down 0.7%
Shares of NYSE HNGE traded down $0.33 during trading on Monday, reaching $46.62. 506,789 shares of the stock traded hands, compared to its average volume of 1,103,514. Hinge Health has a 52-week low of $33.42 and a 52-week high of $52.16.
About Hinge Health
(
Get Free Report)
Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.
Featured Stories
Before you consider Hinge Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hinge Health wasn't on the list.
While Hinge Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
